Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

[Prevalence, potential risk factors and sequelae of diastasis recti abdominis].

Gitta S, Magyar Z, Tardi P, Füge I, Járomi M, Ács P, Garai J, Bódis J, Hock M.

Orv Hetil. 2017 Mar;158(12):454-460. doi: 10.1556/650.2017.30703. Hungarian.

PMID:
28328249
2.

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.

Gordon MJ, Tardi P, Loriaux MM, Spurgeon SE, Traer E, Kovacsovics T, Mayer LD, Tyner JW.

Leuk Res. 2017 Feb;53:39-49. doi: 10.1016/j.leukres.2016.12.002. Epub 2016 Dec 12.

PMID:
28013106
3.

Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomes.

Tardi P, Wan CP, Mayer L.

J Drug Target. 2016 Nov;24(9):797-804. Epub 2016 May 16. Review.

PMID:
27143215
4.

Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion.

Stern ST, Zou P, Skoczen S, Xie S, Liboiron B, Harasym T, Tardi P, Mayer LD, McNeil SE.

J Control Release. 2013 Dec 10;172(2):558-67. doi: 10.1016/j.jconrel.2013.04.025. Epub 2013 May 9.

5.

Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations.

Zisman N, Dos Santos N, Johnstone S, Tsang A, Bermudes D, Mayer L, Tardi P.

Chemother Res Pract. 2011;2011:213848. doi: 10.1155/2011/213848. Epub 2011 Jan 24.

6.

The use of radioactive marker as a tool to evaluate the drug release in plasma and particle biodistribution of block copolymer nanoparticles.

Johnstone S, Ansell S, Xie S, Mayer L, Tardi P.

J Drug Deliv. 2011;2011:349206. doi: 10.1155/2011/349206. Epub 2011 Jul 7.

7.

Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.

Dicko A, Mayer LD, Tardi PG.

Expert Opin Drug Deliv. 2010 Dec;7(12):1329-41. doi: 10.1517/17425247.2010.538678. Review.

PMID:
21118030
8.

Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.

Lim WS, Tardi PG, Xie X, Fan M, Huang R, Ciofani T, Harasym TO, Mayer LD.

Leuk Lymphoma. 2010 Aug;51(8):1536-42. doi: 10.3109/10428194.2010.490312.

PMID:
20528246
9.

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.

Lim WS, Tardi PG, Dos Santos N, Xie X, Fan M, Liboiron BD, Huang X, Harasym TO, Bermudes D, Mayer LD.

Leuk Res. 2010 Sep;34(9):1214-23. doi: 10.1016/j.leukres.2010.01.015. Epub 2010 Feb 6.

PMID:
20138667
10.

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.

Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, Tsang AW, Bermudes DG, Mayer LD.

Mol Cancer Ther. 2009 Aug;8(8):2266-75. doi: 10.1158/1535-7163.MCT-09-0243. Epub 2009 Aug 11.

11.

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, Harvie P, Bermudes D, Mayer L.

Leuk Res. 2009 Jan;33(1):129-39. doi: 10.1016/j.leukres.2008.06.028. Epub 2008 Aug 3.

PMID:
18676016
12.

Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates.

Ansell SM, Johnstone SA, Tardi PG, Lo L, Xie S, Shu Y, Harasym TO, Harasym NL, Williams L, Bermudes D, Liboiron BD, Saad W, Prud'homme RK, Mayer LD.

J Med Chem. 2008 Jun 12;51(11):3288-96. doi: 10.1021/jm800002y. Epub 2008 May 9.

PMID:
18465845
13.

Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.

Dicko A, Frazier AA, Liboiron BD, Hinderliter A, Ellena JF, Xie X, Cho C, Weber T, Tardi PG, Cabral-Lilly D, Cafiso DS, Mayer LD.

Pharm Res. 2008 Jul;25(7):1702-13. doi: 10.1007/s11095-008-9561-z. Epub 2008 Mar 5.

PMID:
18320294
14.
15.

Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes.

Dicko A, Tardi P, Xie X, Mayer L.

Int J Pharm. 2007 Jun 7;337(1-2):219-28. Epub 2007 Jan 9.

PMID:
17270372
16.

Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.

Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD.

Biochim Biophys Acta. 2007 Mar;1768(3):678-87. Epub 2006 Dec 6.

17.

In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.

Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB.

Eur J Pharm Biopharm. 2007 Mar;65(3):289-99. Epub 2006 Oct 17.

PMID:
17123800
18.

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.

Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS.

Mol Cancer Ther. 2006 Jul;5(7):1854-63.

19.

Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.

Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB.

J Control Release. 2005 Jun 20;105(1-2):89-105.

PMID:
15878792
20.

Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.

Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB.

Clin Cancer Res. 2004 Oct 1;10(19):6638-49.

21.

Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes.

Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB.

Biochim Biophys Acta. 2002 Apr 12;1561(2):188-201.

22.

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Waterhouse DN, Tardi PG, Mayer LD, Bally MB.

Drug Saf. 2001;24(12):903-20. Review.

PMID:
11735647
23.

Doxorubicin entrapped within liposome-associated antigens results in a selective inhibition of the antibody response to the linked antigen.

Oja C, Tardi P, Schutze-Redelmeier M, Cullis PR.

Biochim Biophys Acta. 2000 Sep 29;1468(1-2):31-40.

24.

Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.

Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD.

Cancer Res. 2000 Jul 1;60(13):3389-93.

25.

Clearance properties of liposomes involving conjugated proteins for targeting.

Tardi P, Bally MB, Harasym TO.

Adv Drug Deliv Rev. 1998 Jun 8;32(1-2):99-118.

PMID:
10837638
26.

Antibody conjugation methods for active targeting of liposomes.

Ansell SM, Harasym TO, Tardi PG, Buchkowsky SS, Bally MB, Cullis PR.

Methods Mol Med. 2000;25:51-68. doi: 10.1385/1-59259-075-6:51.

PMID:
21318840
27.

Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties.

Zhang YP, Sekirov L, Saravolac EG, Wheeler JJ, Tardi P, Clow K, Leng E, Sun R, Cullis PR, Scherrer P.

Gene Ther. 1999 Aug;6(8):1438-47.

28.

An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin.

Tardi PG, Swartz EN, Harasym TO, Cullis PR, Bally MB.

J Immunol Methods. 1997 Dec 29;210(2):137-48.

PMID:
9520297
29.

3-(2-pyridyldithio)propionic acid hydrazide as a cross-linker in the formation of liposome-antibody conjugates.

Ansell SM, Tardi PG, Buchkowsky SS.

Bioconjug Chem. 1996 Jul-Aug;7(4):490-6.

PMID:
8853463
30.

Liposomal doxorubicin.

Tardi PG, Boman NL, Cullis PR.

J Drug Target. 1996;4(3):129-40. Review.

PMID:
8959485
31.

Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes.

Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR, Bally MB.

J Pharmacol Exp Ther. 1995 Dec;275(3):1177-84.

PMID:
8531079
32.

The modulation of phosphatidylinositol biosynthesis in hamster hearts by methyl lidocaine.

Lee E, Tardi PG, Man RY, Choy PC.

Biochem J. 1995 Aug 1;309 ( Pt 3):871-6.

33.

Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes.

Harasym TO, Tardi P, Longman SA, Ansell SM, Bally MB, Cullis PR, Choi LS.

Bioconjug Chem. 1995 Mar-Apr;6(2):187-94.

PMID:
7599262
34.

Effects of selenium supplement on the de novo biosynthesis of glycerolipids in the isolated rat heart.

Liu SY, Tardi PG, Choy PC, Man RY.

Biochim Biophys Acta. 1993 Nov 3;1170(3):307-13.

PMID:
8218350
35.

Modulation of phosphatidylethanolamine biosynthesis by exogenous ethanolamine and analogues in the hamster heart.

McMaster CR, Tardi PG, Choy PC.

Mol Cell Biochem. 1992 Oct 21;116(1-2):69-73.

PMID:
1480155
36.
37.

Solubilization and modulation of acyl-CoA:1-acyl-glycerophosphocholine acyltransferase activity in rat liver microsomes.

Mukherjee JJ, Tardi PG, Choy PC.

Biochim Biophys Acta. 1992 Jan 3;1123(1):27-32.

PMID:
1730043
38.

The quantitation of long-chain acyl-CoA in mammalian tissue.

Tardi PG, Mukherjee JJ, Choy PC.

Lipids. 1992 Jan;27(1):65-7.

PMID:
1608307
39.

Lysophosphatidylcholine acyltransferase.

Choy PC, Tardi PG, Mukherjee JJ.

Methods Enzymol. 1992;209:80-6. No abstract available.

PMID:
1495439
40.

The effect of methyl lidocaine on lysophospholipid metabolism in hamster heart.

Tardi PG, Man RY, McMaster CR, Choy PC.

Biochem Cell Biol. 1990 Apr;68(4):745-50.

PMID:
2222999

Supplemental Content

Support Center